Applera ABI announced second-quarter results January 24. While the firm's revenues continue to track below our estimates (Applera now expects just mid-single-digit sales growth in its Applied Biosystems group for the full year), the firm has compensated by significantly cutting costs. For this ... Applera ABI announced fourth-quarter results Wednesday that were in line with our expectations, so we are sticking with our fair value estimate. Applera's total revenue for the quarter grew 5%, to $566 million, mainly because of another solid performance from the Applied Biosystems unit, which ... Applera ABI will announce its second-quarter financial results Thursday. While we're keeping our fair value estimate unchanged for now, we look forward to evaluating the firm's progress on several fronts, including the launch of its new sequencing platform. Applera's Applied Biosystems unit ... Just as its business was starting the shed the ill effects of its feverish acquisition pace the past several years, Invitrogen IVGN announced Thursday that it will acquire Applera's ABI Applied Biosystems business for $6.7 billion, or $38 per ABI share. The merger will create a firm with roughly ... Kinetic Concepts KCI announced Friday that Cathy Burzik, president of Applera's ABI Applied Biosystems, will succeed Denny Ware as CEO. KCI announced Ware's intentions to retire just last week with little explanation or direction as to the firm's leadership. We're glad the succession question at ... We recently attended a seminar hosted by Applera's Applied Biosystems ABI that explored the science behind its products. The seminar covered Applied Biosystems' major tool sets, which include DNA sequencers, polymerase chain reaction (PCR)-based technologies, and mass spectrometry equipment. ... Applera ABI reported first-quarter results Oct. 24. Sales came in slightly below our forecasts but profit margins were higher than expected, so we're keeping our fair value estimate unchanged. Applera increased total revenues 6% over the same quarter last year to $517 million, with 5% sales growth ... Applera ABI announced third-quarter results Thursday. While struggles in the mass spectrometry business pushed overall revenue growth below our forecast, Applera significantly improved its profitability, making up for this shortfall. We're sticking with our fair value estimate. Applera's Applied ... On Wednesday, Applera ABI revealed stronger growth trends in the first quarter than we expected on the strength of its Applied Biosystems group. However, we're keeping our fair value estimate at $23 per share for now as we question the sustainability of the 15% sales growth rate over the next three ... Idexx Laboratories IDXX recently introduced its new real-time polymerase chain reaction technology, which allows veterinarians to perform a greater number of diagnostic tests for infectious diseases, like bordetella and coronavirus, in a shorter period. The real-time polymerase chain reaction ...